Erasca opened lower at $14.66, compared with its previous close of $14.98. In the last trading session, the stock traded between $14.14 and $15.01. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Erasca is now worth
$ 72.14
resulting in a loss of
$ 27.86 (27.86%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.71 (-4.74%)
Day High
$15.01
Day Low
$14.14
Day Open
$14.66
Prev Close
$14.98
Volume
11,79,511
1W Return
1.70%
1M Return
0.45%
3M Return
-19.40%
6M Return
56.64%
1Y Return
504.66%
Market Cap ($ Mn)
4,991
PE Ratio
-
PB Ratio
15.59
PEG Ratio
-
ROE
-33.33%
ROCE
-33.71%
EPS (TTM)
$-0.14
1 Week
1.70%
1 Month
0.45%
3 Months
-19.40%
6 Months
56.64%
9 Months
38.41%
Pomerantz investigates Erasca after COO exit triggers stock drop
Pomerantz LLP is investigating Erasca, Inc. for potential securities fraud. Erasca stock fell 9.95% to $13.39 following COO termination announcement. Investigation centers on disclosures regarding leadership realignment. Investors are advised to contact legal counsel for class action participation.
9 days agoBernstein Liebhard probes Erasca fiduciary claims
Bernstein Liebhard LLP investigates Erasca directors for fiduciary breaches. Johnson Fistel previously launched a similar probe into Erasca governance. Investigations stem from patent infringement claims and clinical data disclosures. Shareholders holding stock before January 14, 2025, may have standing.
1mo agoJohnson Fistel probes Erasca over alleged fiduciary duty breaches
Johnson Fistel investigates claims against Erasca officers for alleged fiduciary breaches. Shareholders holding stock since before January 14, 2025 may have standing to sue. Allegations cite patent infringement claims from Revolution Medicines regarding ERAS-0015. Complaint notes ErAS disclosed a patient death and limited cross-study data comparisons.
1mo agoBernstein Liebhard investigates Erasca for potential fiduciary duty breaches
Bernstein Liebhard LLP investigates potential fiduciary duty breaches by Erasca directors and officers. Shareholders who purchased ERAS shares before January 14, 2025 are urged to contact the firm. The probe seeks to determine if leadership acted in shareholder best interests.
1mo agoErasca secures FDA fast track designation for pancreatic cancer drug
FDA grants Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. Phase 1 trial shows 57% uORR8wk in second-line or later KRAS G12X pancreatic cancer patients. Three potentially registration-enabling trials planned across pancreatic and lung cancers. Additional monotherapy and combination data expected in H1 2027.
2mo agoErasca Q2 EPS of $(0.14) misses $(0.11) estimate on R&D spend
Erasca Inc. missed Q2 2026 EPS estimates with a loss of $(0.14) per share versus the expected $(0.11), reflecting a 16.67% widening of losses compared to the prior year. The miss was driven by increased R&D and G&A expenses totaling $47.6 million, offsetting strong liquidity from a recent $632.5 million capital raise. Clinical progress remains positive with promising Phase 1 data for ERAS-0015.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Erasca is now worth
$ 72.14
resulting in a loss of
$ 27.86 (27.86%)
Note: Past profits do not guarantee future returns.
